SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
Part of Cancer clinical trials.
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old, and you can sign consent to join.
- Your nasopharyngeal cancer has already spread, and you have not had metastatic treatment before.
- At least one tumor spot can be treated with SBRT radiation.
- Your overall health must be strong enough for treatment (ECOG 0–1, and doctors expect you can complete therapy).
- You do not have adenocarcinoma or sarcoma in the nasopharynx.
- If you can get pregnant or have a pregnancy-capable partner, you must use effective birth control during the study and for 150 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation can help people whose nasopharyngeal cancer has spread to the lungs or chest area. The treatment aims to shrink tumors and may improve outcomes for patients in this situation.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a combination of chemotherapy (three drugs: docetaxel, cisplatin, and fluorouracil) plus an immunotherapy drug (a PD-1 inhibitor, which helps your immune system fight cancer) given before the standard radiation treatment for nasopharyngeal cancer. The goal is to see if this upfront treatment can improve outcomes in patients whose cancer has not spread to distant parts of the body.
Hear when a new Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.